1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis

Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis

  • July 2015
  • -
  • IQ4I Research & Consultancy Pvt. Ltd
  • -
  • 112 pages

“Nonalcoholicsteatohepatitis(NASH)PipelineAnalysis”givescomprehensiveinsightonthevariousdrugsbeingdevelopedforthetreatmentofNASH.Thereportcoversallthedrugsbeingdevelopedinvariousphases(Discovery,Preclinical&Clinicaldevelopment).Thepipelinefocusesonnovelmedicinescoveringsmallmolecules,monoclonalantibodies,RecombinantproteinsandRNA-basedtherapeutics,butexcludesOff-label,symptomreliefdrugs,genericcombinations.ThereportalsocovershottargetsinresearchforNASHtreatmentsanddiseaseprogressionbiomarkers.
ThisreportenablesPharmaceutical/Biotechcompanies,Academicinstitutes,Individualresearchers,Investors,Medicaltechnologycompanies,Serviceprovidersandotherassociatedstakeholderstoidentifyandanalyzetheavailablelicensing/collaborativecommercialopportunitiesintheNonalcoholicsteatohepatitis(NASH)Drugmarket.ThereportalsoprovidesstrategicinsightsonmedicinesthatarelikelytohaveanimpactonfutureNASHtreatmentspace.
NASHisassociatedwithfattyliver,hepaticinflammation,hepatocyteinjuryandfibrogenesisandmayworsenintofibrosisorcirrhosis,liverfailureandrarelyintolivercancer.Currently,therearenoapproveddrugsforNASHbyU.S.FoodandDrugAdministration(FDA)andthereahighunmetclinicalneed.NASH,ifuntreatedcanprogresstoliver-destroyingcirrhosisandpotentiallycancer.MajorityoftheNASHpipelinedrugsarefromspecialisedsmalltomidpharmaceutical&biotechcompanies.AssomeofthecandidatesarenearingkeyR&Dmilestones,thereisahugecompetitionamonglargepharmaceuticalandbiotechcompaniestoacquiretheseassets.Gilead’sacquisitionofPhenexFXRprogram&Boehringer’sacquisitionofNASHclinicalassetfromPharmaxissupportsthistrend.DiagnosisofNASHstillrequireshistologicalconfirmationandthereisagreatdemandforspecificnon-invasivediagnosisfordistinguishingNASHfromotherliverdiseases.Therefore,thereisaneedtodevelopbetterdiagnosticandtherapeuticstrategiesforpatientswithNASH.
ThereisatremendousopportunityforupcomingtherapiesspecifictoNASHsuchasMAbs,RNA-basedtherapies&Recombinantproteins.ThesemodalitiesmayprovideAnti-fibrosis,Anti-inflammatoryandmetabolicbenefits.

Table Of Contents

Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis
REPORT DESCRIPTION INTRODUCTION
- Causes and Symptoms
- Diagnosis
- Unmet needs
- Current therapies
HOT TARGETS, MECHANISMS and THERAPIES
- Novel Disease mechanisms and therapies
- Leading and hot targets of NASH
- Novel targets of NASH
- NASH biomarkers - Genes involved in NASH
MARKET DATA
- Forecasting model
- Market dynamics
- Market sizing
- NASH Deals
PIPELINE ANALYSIS
- Development stage
- Leading players
- Therapeutic segmentation
- Target analysis
- Innovative approaches
Small molecules
- Pipeline
- Competitive landscape Large molecules
- Competitive landscape RNA-BASED THERAPY
- Pipeline
- Competitive landscape RECOMBINANT PROTEINS
- Pipeline
- Competitive landscape ANTIBODIES
- Pipeline
- Competitive landscape LARGE MOLECULES (UNSPECIFIED)
- Pipeline
OTHER MOLECULES
- Pipeline
NASH DRUG ANALYSIS BASED ON MECHANISM
MAJOR PLAYERS
- Company Profiles
- Overview, Pipeline and Deals

companies mentioned

BOEHRINGER INGELHEIM GMBH
CERENIS THERAPEUTICS CONNEXIOS LIFE SYSTEMS
GALECTIN THERAPEUTICS
GENFIT
GILEAD SCIENCES INC
INTERCEPT PHARMACEUTICALS
ISLET SCIENCES
NGM BIOPHARMACEUTICALS NIMBUS THERAPEUTICS VERVA PHARMACEUTICALS VIKING THERAPEUTICS

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Summary Melanoma is a type of cancer that begins in the ...

Breakthrough Therapies: Market Dynamics and Investment Opportunities

Breakthrough Therapies: Market Dynamics and Investment Opportunities

  • $ 6650
  • Industry report
  • January 2017
  • by BCC Research

Use this report to: - Analyze the challenges and opportunities of developing breakthrough therapies, compare difference fast track drug development approaches and the potential risk and rewards of gaining ...

Alpha Mannosidosis Market and Enzyme Replacement Therapy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Alpha Mannosidosis Market and Enzyme Replacement Therapy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Alpha Mannosidosis Market: Overview With increase in the incidence of alpha mannosidosis worldwide the market for treatment is expected to grow in coming years. Alpha Mannosidosis is a rare inherited ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.